The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer | MicrobiomeTrials← Back to trialsNCT03841617
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2019-07-29Est. Completion: 2035-11-01
Enrollment target: 30 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Papillary Thyroid Microcarcinoma
Researchers in this study aim to prove the safety and efficacy of radiofrequency ablation in the treatment of a carefull…
Budapest, HungaryCompleted Dec 31, 2025
Medulloblastoma
This randomized phase III trial is studying how well standard-dose radiation therapy works compared to reduced-dose radi…
Birmingham, United StatesCompleted Mar 31, 2016
The goal of this clinical trial is to evaluate the usefulness and effectiveness of a newly developed artificial intellig…
Tianjin, ChinaEst. completion Aug 1, 2026